27th German Cancer Congress Berlin 2006
German Cancer Society (Frankfurt/M.)
22. - 26.03.2006, Berlin
Pancreatic Cancer and Cancer of Unknown Primary (CUP)
Meeting Abstract
(OP119)
[Full Text]
RNAi-based knockdown of bcl-2 sensitises pancreatic cancer to gemcitabine treatment
Ocker M, Neureiter D, Sass G, Hahn EG, Herold C[Full Text]
Meeting Abstract
(OP120)
[Full Text]
Adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer - a randomised, prospective, multicenter phase III study (CONKO-001)
Oettle H, Roll L, Neuhaus P, Post S, Gellert K, Ridwelski K, Schramm H, Zülke C, Ziske J, Burkart C, Niedergethman M, Fahlke J, Langrehr J, Riess H[Full Text]
Meeting Abstract
(OP121)
[Full Text]
Prognostische Relevanz der Lymphgefäßdichte im Pankreaskarzinom
Kleespies A, Assmann G, Wilkowski R, Löhrs U, Diebold J, Jauch KW, Bruns C[Full Text]
Meeting Abstract
(OP122)
[Full Text]
Lymph Node Status and Prognosis of Malignant Endocrine Pancreatic Tumors after Curative Surgical Resection
Demir R, Meyer T, Merkel S, Hohenberger W[Full Text]
Meeting Abstract
(OP123)
[Full Text]
Poly (ADP-ribose)polymerase inhibitor 3-aminobenzamide in combination with gemcitabine shows strong antitumor activity in pancreatic cancer cells
Jacob D, Bahra M, Langrehr J, Neuhaus P, Neumann U[Full Text]
Meeting Abstract
(OP124)
[Full Text]
5-lipoxygenase is a new key player and tumor promoter in pancreatic carcinogenesis
Hennig R, Esposito I, Grippo P, Rao SM, Giese N, Büchler MW, Friess H, Bell RH, Adrian TE[Full Text]
Meeting Abstract
(OP125)
[Full Text]
A randomized, prospective phase III second line trial of patiens with gemcitabine resistant advanced pancreatic cancer (CONKO 003).
Pelzer U, Roll L, Stieler J, Hilbig A, Schwaner I, Adler M, Seraphin J, Dörken B, Riess H, Oettle H[Full Text]
Meeting Abstract
(PO126)
[Full Text]
Effects of inducible p53 reconstitution in an orthotopic mouse model of pancreatic cancer
Otto N, Schulz P, Scholz A, Rexin A, Hauff P, Schirner M, Wiedenmann B, Detjen K, Rosewicz S[Full Text]
Meeting Abstract
(PO127)
[Full Text]
Phase II Study of First Line Sorafenib (BAY 43-9006) in Patients with Locally Advanced and/or Metastatic Pancreatic Cancer – a Study of the Central European Society for Anticancer Drug Research - EWIV (CESAR)
Scheulen ME, Mross K, Dittrich C, Hochhaus A, Morant R, Köberle D, Krauß J, Frost A, Flashar C, Edler L, Scheuring U, Strumberg D[Full Text]
Meeting Abstract
(PO128)
[Full Text]
Matuzumab (EMD 72000) und Gemcitabine im tierexperimentellen Pankreaskarzinom
Kleespies A, Mantell O, Amendt C, Yezhelyev M, Guba M, Jauch KW, Bruns C[Full Text]
Meeting Abstract
(PO129)
[Full Text]
Zoledronic Acid has Direct anti-Proliferative and anti-Metastatic Effect on Pancreatic Carcinoma Cells and Acts an Antigen for γ2 γ/δ T cells
Märten A, von Lilienfeld-Toal M, Büchler M, Jäger D, Schmidt J[Full Text]
Meeting Abstract
(PO130)
[Full Text]
Immunomonitoring of the CapRI Trial: First Results
Märten A, Jäger D, Büchler M, Schmidt J[Full Text]
Meeting Abstract
(PO131)
[Full Text]
Sonic Hedgehog(SHH) in pancreatic cancer: Effect of the small molecule inhibitor Hh-Antag
Bahra M, Koch A, Langrehr JM, Hartmann W, Schüller U, Schulz N, Neuhaus P, Pietsch T[Full Text]
Meeting Abstract
(PO132)
[Full Text]
Nuclear DNA content and survival rates of patients with pancreatic cancer: a prospective study on 64 cases
Seehofer D, Al-Abadi H, Langrehr J, Weidemann H, Bahra M, Abou-Rebyh H, Veltzke-Schlieker, W, Neuhaus P[Full Text]
Meeting Abstract
(PO133)
[Full Text]
Severe Hypocalcaemia During Therapy With Low-Dose Cisplatin, 5-Fluorouracil And Interferon alpha
Hoffmann K, Lindel K, Fritz S, Maerten A, Jaeger D, Buechler M, Schmidt J[Full Text]
Meeting Abstract
(PO134)
[Full Text]
Locally Advanced Pancreatic Cancer - can combined Chemo-/Radiotherapy prolong Survival? Single-Center Experience on Mitomycin/Fluorouracil-based Chemo-/Radiotherapy
Grothaus-Pinke B, Rohn R, Heike M[Full Text]
Meeting Abstract
(PO135)
[Full Text]
A randomized, prospective, multicenter, phase III trial of gemcitabin (g), 5-fluorouracil (5-fu), folinic acid (fa) vs. gemcitabine alone in patients with advanced pancreatic cancer (CONKO 002)
Pelzer U, Helm A, Niedergehtmann M, Schmidt-Wolf I, Moik M, Hammer C, Zippel K, Weigang-Köhler K, Stauch M, Riess H, Oettle H[Full Text]
Meeting Abstract
(PO136)
[Full Text]
A Prospective, Randomized trial Of Simultaneous Pancreatic cancer treatment with Enoxaparin and ChemoTherapy (PROSPECT – CONKO 004)
Pelzer U, Hilbig A, Stieler J, Roll L, Stauch M, Opitz B, Scholten T, Zippel K, Hahnfeld S, Dörken B, Riess H, Oettle H[Full Text]
Meeting Abstract
(PO137)
[Full Text]
Treatment of patients with advanced pancreatic cancer using gemcitabine, cisplatin, 5-fluorouracil, folinic acid (GFFC) and concomitant low-molecular weight heparin (enoxaparin) in an outpatient setting: a pilot study
Hilbig A, Pelzer U, Stieler J, Roll L, Bernd D, Riess H, Oettle H[Full Text]
Meeting Abstract
(PO138)
[Full Text]
Phase III Trial CapRI (adjuvant ChemoRadioImmunotherapy of pancreatic adenocarcinoma) versus 5-FU alone
Märten A, Schmidt J, Märten A, Jäger D, Büchler M[Full Text]
Meeting Abstract
(PO139)
[Full Text]
Report on recruiting in a centre for the trial "Preoperative chemoradiotherapy in locally resectable adenocarcinoma of the pancreatic head without metastasis”
Golcher H, Meyer T, Brunner T, Baum U, Böhner C, Papadopoulos T, Grabenbauer G, Hohenberger W[Full Text]